The Delta-like (DLK1) gene is overexpressed in CD34 þ cells from myelodysplastic syndrome (MDS) patients. DLK1 encodes an EGF-like homeotic transmembrane protein homologous to the notch/delta/serrate family. Although exogenous DLK1 promotes maintenance of murine hematopoietic stem cells, the functional effects of DLK1 overexpression in hematopoietic cells are unknown. We show that ectopically expressed DLK1 significantly inhibits differentiation and proliferation of human promyelocytic HL-60 cells. Unlike preadipocytes, where proteolytic processing of membrane-bound protein and release of a soluble form mediates differentiation inhibition, proteolytic release of the extracellular domain was not required for inhibition of hematopoietic cell differentiation. However, intracellular domain interactions were critical to this DLK1 function. We conclude that DLK1 overexpression in hematopoietic cells has important functional consequences. Our studies identify novel molecular mechanisms and indicate that DLK1 has activity both as a soluble and a transmembrane expressed protein. Our results support further investigation of the role of DLK1 in abnormal hematopoiesis in MDS.
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The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by impaired hematopoietic cell differentiation, ineffective hematopoiesis, peripheral cytopenias and frequent evolution to acute myelogenous leukemia (Greenberg et al., 2002) . The molecular pathogenesis of MDS remains poorly understood. Lack of knowledge of molecular mechanisms underlying abnormal hematopoiesis in MDS has impaired progress in development of effective treatments. Recent studies indicate that increased expression of the Delta-like-1 (DLK1) gene is frequently observed in CD34 þ cells from MDS patients (Miyazato et al., 2001; Hofmann et al., 2002; Langer et al., 2004) . The DLK1 gene encodes a transmembrane homeotic protein with six epidermal growth factor like repeats, homologous to the notch/delta/serrate family but lacking the DSL domain ( Figure 1a ). DLK1, preadipocyte factor 1 (PREF1), fetal antigen-1 and pG2 are variant products of the same gene (Jensen et al., 1994; Lee et al., 1995; Bachmann et al., 1996) . DLK1 is expressed in neuroendocrine tumors and small-cell lung carcinoma lines as well as normal adrenal glands and placentae (Laborda et al., 1993; Costaglioli et al., 2001; Van Limpt et al., 2003) . Moore et al. (1997) showed that DLK1 was preferentially expressed in fetal stromal cell lines, which supported hematopoietic stem cell growth but not in nonsupportive lines, and directly demonstrated that exogenous DLK1 was a positive regulator of murine stem cell growth. DLK1 also regulates pre-B cell and thymocyte growth (Bauer et al., 1998; Kaneta et al., 2000) . However, these studies have focused on the effects of exogenous DLK1 on hematopoietic cells, and the functional consequences of aberrant, intrinsic DLK1 overexpression in human hematopoietic cells are not known.
To study DLK1 effects on human hematopoietic cell differentiation and growth, we used an approach of ectopic expression of human DLK1 in promyelocytic HL-60 cells (American Type Culture Collection, Rockville, MD, USA), lacking intrinsic DLK1 expression. HL-60 promyelocytic cells were maintained in IMDM with 20% FCS. cDNAs encoding full-length human DLK1 were amplified from a placental library (BD Clontech, Palo Alto, CA, USA) using polymerase chain reaction (PCR) amplification. DLK1 genes with deletions of specific functional domains as described in the Results were also generated by PCR amplification. After confirmation of sequence, wild type and mutant DLK1 genes were subcloned into the EcoR1 site of the MIG-R1 retroviral vector (a gift from Dr Warren Pear, University of Pennsylvania, Philadelphia, PA, USA). Infectious virions were produced by transient transfection of 293 cells as previously described (Ramaraj et al., 2004) , and used to transduce HL-60 cells. GFP-positive cells were selected by flow cytometry sorting after 48 h. DLK expression was confirmed by RT-PCR.
DLK1 expressing HL-60 cells (HL-60-DLK1) and control cells expressing GFP alone (HL60-R1) both expressed low levels of CD11b, a myeloid differentiation marker, when cultured under standard conditions without addition of differentiating agents ( Figure 1b) . To induce differentiation, HL-60 cells were exposed to 1 mM all-trans-retinoic acid (ATRA; Sigma), 1.25% DMSO (Sigma) or 2 nM tetrahydro-phorbol-ester acid (PMA; Sigma) to induce differentiation. Cells were cultured at a density of 5 Â 10 4 /ml with or without differentiationinducing agents, harvested at the indicated time points and differentiation evaluated by CD11b expression, assessment of morphology following Wright-Giemsa staining, and nitro-blue toluidine ( Figure 1 Effects of DLK1 and DLK1 mutants on promyelocytic differentiation. (a) The DLK1 gene encodes a transmembrane protein with six epidermal growth factor like repeats with two proteolytic sites allowing release of both small and large soluble extracellular fragments. DLK1 mutants were obtained through deletion of specific functional domains. DLK-EC, containing the extracellular part of DLK1 molecule, is expressed as soluble form only. DLK-dIC has a deletion of the cytoplasmic tail. DLK-ALT has deletion of the proximal protease sensitive domain. HL-60 cells expressing DLK1 or controls expressing GFP alone (R1) were cultured in the absence and in the presence of (b) ATRA (1 mM) (n ¼ 6), (c) DMSO (1.25%) (n ¼ 3) or (d) PMA (2 nM) (n ¼ 3). CD11b expression was analysed by FACS at time points shown. (e) HL-60 cells transduced with wild-type DLK1 and different DLK1 mutants (n ¼ 4) were cultured with or without ATRA (1 mM) for 5 days and CD11b expression was analysed by FACS. Results represent the mean7s.e.m. of multiple experiments. P-values were calculated using two-way ANOVA. Significant differences between groups are shown: *Po0.001, **Po0.0001 duction of expression of CD11b following exposure to the differentiating agents ATRA (Po0.0001, Figure 1b) , DMSO (Po0.0001, Figure 1c) or PMA (Po0.0001, Figure 1d ) compared with HL-60-R1 controls. Reduced differentiation in HL-60-DLK1 cells was confirmed by morphological analysis and NBT reduction assays (data not shown). HL-60-DLK1 cells did not demonstrate significant changes in apoptosis compared with HL-60-R1 cells following differentiation induction (data not shown).
DLK1, like other homeotic proteins, has also been reported to regulate differentiation of other tissues. The DLK1 variant, PREF1, inhibits preadipocyte differentiation to adipocytes as well as adipogenic and osteogenic differentiation of bone marrow mesenchymal stem cells (Smas and Sul, 1993; Smas et al., 1997; Garces et al., 1999; Sul et al., 2000; Abdallah et al., 2004) . Inhibition of preadipocyte differentiation requires proteolytic cleavage at a membrane proximal site and release of a large soluble form of the extracellular domain, which retains biological activity (Smas et al., 1997; Garces et al., 1999; Mei et al., 2002) . To explore mechanisms underlying inhibition of HL-60 differentiation by DLK1, we generated mutant genes with deletions of specific functional domains (Figure 1a ). These included: (i) DLK1-EC, encoding the full extracellular portion of DLK1 and a signal sequence, expressed as the extracellular soluble form only; (ii) DLK1-dIC with deletion of the intracytoplasmic tail, expressed as a transmembrane form capable of proteolytic cleavage and release of the extracellular portion; and (iii) DLK1-ALT, an alternatively spliced form of DLK1 containing the intracytoplasmic tail but lacking the membrane-proximal protease-sensitive site, and therefore incapable of release of the large extracellular fragment. Inhibition of ATRA induced differentiation of HL-60 cells was not observed with the DLK1-EC and DLK1-dIC mutants, which lack the intracytoplasmic tail ( Figure 1f) . However, DLK1-ALT inhibited HL-60 differentiation to a similar extent as wild-type DLK1. These results indicate that in contrast to PREF1 signaling in adipogenesis (Mei et al., 2002) , DLK1 mediated inhibition of hematopoietic cell differentiation was not mediated by and did not require proteolytic cleavage and release of the extracellular domain. On the other hand, intracytoplasmic domain interactions were critical to DLK1 function. Therefore, DLK1 expressed in hematopoietic cells appears to function as a transmembrane protein that transduces intracellular differentiation inhibitory signals and/or affects mechanisms that regulate cell differentiation via intracellular domain interactions. These studies provide new insights into DLK1 physiology, and suggest that the molecule can function both as ligand and receptor.
DLK1 expression was associated with inhibition of HL-60 cell proliferation when cultured under standard conditions (Figure 2a) . No change in cell viability was apparent (data not shown). Cell cycle synchronization was performed by incubating cells with nocodazol (200 ng/ml; Sigma) for 16 h. Cells were then washed twice and incubated in the fresh media without nocodazol. Cell cycle profiles were analysed every 2 h for 16 h using propidium iodide labeling of DNA (PI; Molecular Probes, Eugene, OR, USA) as previously described (Bhatia et al., 2000) . Cell cycle analysis revealed that DLK1 expressing HL-60 cells exhibited slower progress through G0/G1 phase into S phase than controls following release from G2/M phase synchronization with Nocodazol treatment (Figure 2b ). DLK1 has been observed to have proliferation inhibitory effects in other cell systems, including Balb/c 3T3 cells (Baladron et al., 2002) and RINm5F insulinoma cells (Friedrichsen et al., 2003) . The DLK1 homolog, Notch1, can also reduce hematopoietic cell proliferation by altering cell-cycle kinetics (Walker et al., 1999; Ye et al., 2004) . We studied the effects of DLK1 mutations on cell proliferation. DLK1-dIC inhibited proliferation to a similar extent as wild-type DLK1, whereas DLK1-ALT resulted in further reduction in proliferation (Figure 2c ). In contrast, DLK1-EC significantly enhanced cell proliferation compared with wild-type DLK1. Increased growth suppression by DLK1-ALT suggests that release of the extracellular domain by proteolytic cleavage has a proliferation stimulatory effect. This is consistent with the significant enhancement of proliferation seen with DLK1-EC, which encodes only the extracellular domain in a soluble form. The increased suppression seen with DLK1-ALT also indicates that transmembranously expressed protein has a proliferation inhibitory effect. The overall inhibition of proliferation seen with wild-type DLK indicates that inhibitory effects of transmembrane protein predominates over the proliferation stimulatory effect of the extracellular portion in cells expressing the wild-type protein. The observation that DLK1-dIC inhibited proliferation to a similar extent as wild-type DLK1 indicates that the inhibitory effects of DLK1 on proliferation, although requiring expression as a transmembrane molecule, may not require intracellular domain mediated interactions, and in this way differ from the differentiation inhibitory effects of DLK.
The effects of DLK1 on differentiation are prominent and are consistent with the observation that primary MDS hematopoiesis is characterized by impaired differentiation, cellular dysplasia, ineffective hematopoiesis and peripheral cytopenias (Greenberg et al., 2002) . The effects of DLK1 expression on cell growth appears to be harder to relate to the observation of increased proliferation of hematopoietic cells in MDS marrow (Raza et al., 1997) . However, the proliferation status of cells at different stages of differentiation has not been well described. Moreover, alterations in intracellular and extraneous factors other than DLK1 are likely to contribute to altered proliferation of MDS hematopoietic cells (Allampallam et al., 1999; Silver et al., 2004) . DLK1 can be expressed on cells in either a wild-type form or an alternatively spliced form that is not subject to proteolytic cleavage. The results of PCR assays performed in our laboratory (results not shown), as well as results reported by others (Miyazato et al., 2001) , indicate that the wild-type DLK1 transcript is present in MDS progenitor cells. Although we have not specifically evaluated for coexpression of alternatively spliced DLK, this does not appear to of critical importance since overexpression of both wild type and the alternatively spliced form of DLK1 results in inhibition of HL-60 cell differentiation and proliferation. The current results must be interpreted with some caution since the HL-60 cell line, while being a useful model for hematopoietic cell growth regulation, is considerably more differentiated than the CD34 þ stem/progenitor cells in which MDS originates. In addition, immortalized cell lines Results represent the Mean7s.e.m. of multiple experiments. P-values were calculated using two-way ANOVA. Significant differences between groups are shown: *Po0.05, **Po0.01, ***Po0.0001 may differ in their response to DLK1 overexpression compared to primary stem/progenitor cells. We have initiated experiments to investigate levels of DLK expression at different stages of MDS and normal hematopoietic cell differentiation, and to evaluate the effect of DLK overexpression and inhibition in primary stem/progenitor cells, as well as more differentiated populations.
In conclusion, our studies indicate that DLK1 overexpression in human promyelocytic cells has important functional consequences and identify novel molecular mechanisms for these effects. Impaired differentiation and reduced hematopoietic cell production are important features of MDS hematopoiesis. Our results support further investigation of the role of DLK1 in normal hematopoiesis and its potential role in hematopoietic abnormalities in MDS.
